Model Investigator Initiated Study Agreement (DRAFT v0.4 March 2024)Investigator Initiated Study Agreement • April 2nd, 2024 • England and Wales
this investigator-led template may be used when NHS organisations sponsor non-commercial research that is led and designed by an NHS-employed Chief Investigator, but is funded and / or supported in-kind by a company. The support in kind may be supply of free product or other non-financial contribution to the research
Certain confidential information contained in this document, marked by brackets and asterisks ([***]), has been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K, because it (i) is not material and (ii) would be competitively harmful if...Investigator-Initiated Study Agreement • April 6th, 2021 • ASTROTECH Corp • Laboratory analytical instruments • Delaware
This Investigator-Initiated Study Agreement (“Agreement”) dated as of the 15th day of March, 2021 (“Effective Date”), is by and between BreathTech Corporation, (“Company”), a wholly owned subsidiary of Astrotech Corporation with offices at 2028 E. Ben White Blvd. #240-9530, Austin, Texas 78741 and the Cleveland Clinic Foundation (“Institution”), an Ohio non-profit corporation with offices at 9500 Euclid Avenue, Cleveland, Ohio 44195, USA. Institution and Company may herein be referred to individually as a “Party” and collectively as the “Parties”.
INVESTIGATOR INITIATED STUDY AGREEMENTInvestigator Initiated Study Agreement • July 26th, 2021
This Investigator Initiated Study Agreement (this “Agreement”) is dated as of 21 July 2021 (the “Effective Date”) by and between PTC Therapeutics International Ltd., Fifth Floor, 3 Grand Canal Plaza, Grand Canal Street Upper, Dublin 4, D04 EE70, Ireland (“Company”), and University Hospital Brno, located at Jihlavská 20, 625 00, Brno, Czech Republic, represented by prof. MUDr. Jaroslav Štěrba, Ph.D., Director (“Institution”) and
Investigator Initiated Study Agreement (Drug)Investigator Initiated Study Agreement • March 13th, 2020 • BriaCell Therapeutics Corp. • Pharmaceutical preparations • Pennsylvania
This Agreement is entered into by and between Thomas Jefferson University, a Pennsylvania non-profit corporation, with an address at Office of Research Administration, 125 South 9th Street, Second Floor Sheridan Philadelphia, PA 19107, hereinafter called “Institution,” and BriaCell Therapeutics, a corporation with its principal office and place of business at 820 Heinz Avenue, Berkeley, CA 94710, hereinafter called “Sponsor.”
Amendment #1 to Investigator-Initiated Study AgreementInvestigator-Initiated Study Agreement • September 20th, 2024 • ASTROTECH Corp • Laboratory analytical instruments
This F Amendment #1 to the Investigator-Initiated Study Agreement(“Amendment #1”) is entered into as of the date of last signature and made effective as of November 15, 2022 (the “Effective Date”) by and between The Cleveland Clinic Foundation (“Institution”), an Ohio non-profit corporation with offices at 9500 Euclid Avenue, Cleveland, Ohio 44195, and BreathTech Corporation (“Company”) a wholly owned subsidiary of Astrotech Corporation with offices at 2028 E. Ben White Blvd. #240-9530, Austin, Texas 78741.
